Immunotherapy startup Dragonfly, co-founded by KI member Tyler Jacks, announced a strategic research collaboration with pharmaceutical giant Gilead to advance their natural killer cell engager-based immunotherapies for cancer and inflammatory diseases. The partnership opens up broader pipelines for cancer drug development and approvals, and accelerates opportunities for patient impact and major distribution.